1. PepGen faces a class action lawsuit for potential securities fraud. 2. Investors claim misleading statements regarding drug candidate PGN-EDO51's effectiveness. 3. Deficiencies in CONNECT2 study may jeopardize FDA approval, causing investor losses. 4. Class period for affected investors is March 2024 to March 2025. 5. Investors encouraged to join the lawsuit to recoup losses.
The lawsuit indicates significant issues with drug safety and efficacy. Historical examples of similar cases resulted in steep stock declines.
Legal actions and fraud allegations can heavily influence stock prices, often reflecting rapidly in the market.
Immediate negative sentiment expected as the lawsuit reveals alleged misrepresentations. Historical patterns show quick reactions to such news.
LOS ANGELES, Aug. 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against PepGen Inc. ("PepGen" or "the Company") (NASDAQ: PEPG) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between March 7, 2024 through March 3, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 8, 2025.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. PepGen's drug candidate PGN-EDO51 was less safe and effective than it claimed to investors. The Company's CONNECT2 study was deficient for purposes of FDA approval and was dangerous to participants. The Company was likely to halt its CONNECT2 study. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about PepGen, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/pepg-investors-have-opportunity-to-lead-pepgen-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302524017.html
SOURCE The Schall Law Firm